GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for REWIND

REWIND

Official Title

Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND): The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes

Status

Ongoing

Overview

To assess the effect of once-weekly 1.5mg Dulaglutide on CV outcomes when added to the existing anti-hyperglycemic regimen of patients with type-2 diabetes.

Study Design

Phase 3, event-driven, multicenter, international, randomized, double-blind, placebo-controlled, parallel study

Primary Endpoint

Time to first occurrence (after randomization) of the composite endpoint of death from CV causes, nonfatal MI, or nonfatal stroke.

Number of Patients

9901

Number of Sites

404

Number of Countries

24

Study Period

2010–2019

Principal Investigator

Hertzel Gerstein

Program Manager

Tara McCready

Research Coordinator

Stephanie Hall

Collaborators

Eli Lilly